- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06415903
A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
May 14, 2024 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Phase I Study to Evaluate the Safety and Tolerance of TQB3117 Tablets in Patients With Advanced Malignant Cancer
The study is divided into two phases: dose escalation and dose extension.
The dosing regimens include a single-dose study and a multiple-dose study.
It adopts a single-center, open-label, non-randomized, single-arm clinical trial design, where patients with advanced malignant cancer are selected to orally take TQB3117 tablets.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TQB3117 tablets in patients.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
59
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jinming Yu, Doctor
- Phone Number: 13806406293
- Email: sdyujinming@126.com
Study Contact Backup
- Name: Yuping Sun, Doctor
- Phone Number: 0531-67627156
- Email: 13370582181@163.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250117
- The First Affiliated Hospital of Shandong First Medical University
-
Contact:
- Jinming Yu, Doctor
- Phone Number: 13806406293
- Email: sdyujinming@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
- Age: 18 to 75 years old; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Has at least one assessable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria;
- The main organs function well;
- Female patient had no plans to become pregnant and voluntarily took effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug.
Exclusion Criteria:
- There were other malignant tumors in 3 years;
- Has multiple factors affecting oral medication;
- Unalleviated toxicity ≥ grade 1 above CTCAE v5.0 due to any previous therapy, excluding hair loss;
- Major surgical treatment, open biopsy and obvious traumatic injury were performed within 28 days before the study, or have not fully recovered from previous surgery, or are expected to require major surgical surgery during the study period;
- Arteriovenous thrombotic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism;
- Have a history of psychotropic drug abuse and can not quit or have mental disorders;
- Subjects with any severe and / or uncontrolled disease included: active hepatitis, have a history of immunodeficiency;
- Has known symptomatic central nervous system metastases and/or cancerous meningitis;
- Thoracic/abdominal/pericardial effusion with clinical symptoms or requiring repeated drainage, or drainage for the purpose of receiving treatment within one month after receiving the investigational drug for the first time;
- Has participated in other clinical trials within 4 weeks before first dose;
- According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQB3117 tablets
TQB3117 tables is administered as a single dose or multiple dose, ranging from 20 to 180 mg once daily.
Oral administration on fast condition, with each cycle lasting 21 days.
|
TQB3117 is a protein inhibitor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicity (DLT)
Time Frame: At the end of Cycle 1 (each cycle is 21 days)
|
DLT refers to occurrence of drug-related adverse events within the first treatment cycle after subjects receive single-dose or multiple-dose treatment, as defined by the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 toxicity assessment criteria.
|
At the end of Cycle 1 (each cycle is 21 days)
|
Maximum tolerated dose (MTD)
Time Frame: At the end of Cycle 1 (each cycle is 21 days)
|
MTD is defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.
|
At the end of Cycle 1 (each cycle is 21 days)
|
Recommended Phase II Dose (RP2D)
Time Frame: Baseline up to 24 months
|
DLT describes side effects of a drug or other treatment that are serious enough to evaluate RP2D of TQB3117 tablets in adult patients with advanced malignant cancer.
|
Baseline up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events (AE)
Time Frame: 30 days after the last administration
|
The occurrence of all adverse events (AE).
|
30 days after the last administration
|
Serious adverse events (SAE)
Time Frame: 30 days after the last administration
|
The occurrence of all serious adverse events (SAE).
|
30 days after the last administration
|
Time to reach maximum plasma concentration (Tmax)
Time Frame: Day 1 of single dose: pre-dose, at 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7,14 and 21 of cycle1: pre-dose. Day 21of cycle1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
To characterize the pharmacokinetics of TQB3117 by assessment of time to reach maximum plasma concentration after single and multiple dosing.
|
Day 1 of single dose: pre-dose, at 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7,14 and 21 of cycle1: pre-dose. Day 21of cycle1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Peak concentration (Cmax)
Time Frame: Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7,14 and 21 of cycle1: pre-dose. Day 21 of cycle 1: at 0.5,1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
The maximum observed plasma concentration of study drug.
|
Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7,14 and 21 of cycle1: pre-dose. Day 21 of cycle 1: at 0.5,1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Half-life (t1/2)
Time Frame: Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
|
Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Area under the concentration-time curve (AUC [0-infinity]
Time Frame: Day 1 of single dose: pre-dose, at 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose, Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
To characterize the pharmacokinetics of TQB3117 by assessment of area under the plasma concentration time curve from 0 extrapolated to infinity.
|
Day 1 of single dose: pre-dose, at 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose, Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Area under the concentration-time curve (AUC [0-t]
Time Frame: Day 1 of single dose: pre-dose, at 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
To characterize the pharmacokinetics of TQB3117 by assessment of area under the plasma concentration time curve from the first dose to a certain time point.
|
Day 1 of single dose: pre-dose, at 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Apparent clearance (CL/F)
Time Frame: Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.
|
Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Apparent volume of distribution (Vd/F)
Time Frame: Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Apparent volume of distribution of the TQB3117 in plasma.
|
Day 1 of single dose: pre-dose, at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after-dose. Days 7, 14 and 21 of cycle 1: pre-dose. Day 21 of cycle 1: at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after-dose.
|
Objective Response Rate (ORR)
Time Frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks
|
The percentage of complete response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria.
|
From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
August 1, 2026
Study Registration Dates
First Submitted
May 13, 2024
First Submitted That Met QC Criteria
May 14, 2024
First Posted (Actual)
May 16, 2024
Study Record Updates
Last Update Posted (Actual)
May 16, 2024
Last Update Submitted That Met QC Criteria
May 14, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- TQB3117-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Cancer
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingAdvanced Malignant Cancer
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Malignant Cancer
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Recruiting
-
Advanced Integrative Medical Science InstituteRecruitingNeoplasms | Advanced Solid Tumor | Advanced Cancer | Oncology | Neoplasm MalignantUnited States
-
University of California, San FranciscoCompletedIntegrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced CancerAdvanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Mirati Therapeutics Inc.Approved for marketingMetastatic Cancer | Advanced Cancer | Malignant NeoplasmUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedAdvanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Caregiver | Advanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
EpicentRx, Inc.TerminatedMetastatic Cancer | Advanced Cancer | Malignant Solid TumorUnited States
Clinical Trials on TQB3117 tablets
-
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Recruiting
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedInflammatory Bowel DiseasesChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingModerate to Severe Atopic DermatitisChina
-
Shenzhen NewDEL Biotech, Co., LtdShenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.Enrolling by invitation